Bayer AG annual gross margin
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Bayer AG Gross Margin Growth & History (BAYN)
Bayer AG's gross margin was 58.76% for fiscal 2025.
View full Bayer AG company overviewBayer AG annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 58.76% | +4.39 pp |
| 2024 | 2024-12-31 | 54.36% | −4.18 pp |
| 2023 | 2023-12-31 | 58.54% | −2.29 pp |
| 2022 | 2022-12-31 | 60.84% | −1.02 pp |
| 2021 | 2021-12-31 | 61.85% | +8.08 pp |
| 2020 | 2020-12-31 | 53.77% | −6.11 pp |
| 2019 | 2019-12-31 | 59.89% | +2.86 pp |
| 2018 | 2018-12-31 | 57.03% | −10.46 pp |
| 2017 | 2017-12-31 | 67.49% | +10.89 pp |
| 2016 | 2016-12-31 | 56.61% | +2.28 pp |
| 2015 | 2015-12-31 | 54.33% | +2.31 pp |
| 2014 | 2014-12-31 | 52.02% | −0.49 pp |
| 2013 | 2013-12-31 | 52.51% | −2.28 pp |
| 2012 | 2012-12-31 | 54.79% | +1.61 pp |
| 2011 | 2011-12-31 | 53.18% | −3.69 pp |
| 2010 | 2010-12-31 | 56.87% | — |
Bayer AG gross margin trends
Over the last five fiscal years, Bayer AG's gross margin increased from 53.77% to 58.76%, a change of +4.98 percentage points.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as reported gross profit divided by reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bayer AG source filings ↗Community posts
Bayer wins the first Roundup trial following the Supreme Court ruling
A Missouri jury unanimously ruled for Bayer ($BAYN)’s Monsanto unit in a three-plaintiff Roundup case, rejecting design-defect, fraud and negligence claims. It was the first such trial following the US Supreme Court decision that blocked th ...
Bayer’s Nubeqa cuts risk of metastasis or death in prostate trial
Bayer ($BAYN) disclosed interim Phase 3 results showing that adding Nubeqa to hormone therapy and radiation reduced the risk of metastasis or death by 58% in prostate-cancer patients at high risk of recurrence. Four-year metastasis-free sur ...
